Form D · Other
Aurora Spine Corp
Toronto, A6 · CIK 0001598103
Offering snapshot reported Sep 24, 2021 · SEC filing
- Reported sold
- $3.17M Offering amount: $6.24M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 17, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 24, 2021 | Initial | $3,167,826 | No comparison | 3 | SEC filing |
| Sep 24, 2021 | Initial | $0 | No comparison | 1 | SEC filing |
| Feb 20, 2020 | Initial | $198,069 | No comparison | 1 | SEC filing |
| Feb 20, 2020 | Amendment | $198,069 | $0vs Feb 20, 2020 | 1 | SEC filing |
| Mar 18, 2015 | Initial | $400,445 | No comparison | 1 | SEC filing |
| Jan 29, 2014 | Initial | $1,703,749 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $222K
- Finders' fees
- $0
- Form D file number
- 021-414603
Total Remaining to be Sold, is the aggregate purchase price of shares underlying warrants sold in this offering. U.S. dollar amounts are based on the Bank of Canada exchange rate 0.7861 reported on September 17, 2021.
Common Shares and Warrants. Each Warrant will entitle the holder to acquire one Common Share at a exercise price of CAD$0.75 for a period of 36 months from the date of issuance.
Cash commission of C$282,086 and 561,047 Broker Warrants. Each Broker Warrant will entitle the holder thereof to purchase one Common Share at an exercise price of C$0.58 for a period of 36 months from the date of issuance.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| A.G. P. / ALLIANCE GLOBAL PARTNERS | 8361 |
Source: Form D, filed Sep 24, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Chad Clouse | Executive |
| Kenneth E. Fronk | Executive |
| Laszlo Garamszegi | Executive |
| Tracy Graf | Director |
| Ken Gross | Executive |
| Brent Johnston | Executive |
| Jana Kiena | Executive |
| J. Daryl Mac Lellan | Director |
| Daryl Mac Lellan | Director |
| David Meyer | Executive |
| Dave Meyer | Executive |
| Trent Northcutt | Director, Executive |
| David Rosenkrantz | Director |
| Michael Seid | Director |
| Mike Seid | Director |
| Jim Snow | Director |
| James Snow | Director |
Issuer details
Industry: Other (See others in industry)
Address:
20 Holly Street, Suite 300
Toronto, A6, M4S 3B1
Toronto, A6, M4S 3B1